Press Release

AATD (Alpha-1 Antitrypsin Deficiency) Augmentation Therapy Market: Know Why The Global Market is Growing continuously

AATD (Alpha-1 Antitrypsin Deficiency) Augmentation Therapy Market to Grow at 5.9% CAGR to Reach US$ 1959.8 Mn by 2026

The estimated rise in market value from its 2017 value of US$ 1115.5 Mn implies that the market will exhibit a CAGR of 5.9% in the foreacast period. Fortune Business Insights expects that factors such as regulatory approvals and improvements in augmentation therapies will drive the market in this period.

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/aatd-augmentation-therapy-market-100169

Grifols SA’s AlfaCare Program Has Had a Positive Impact on the Global Market

In November 2018, Grifols Sa introduced AlfaCare, a therapy program aimed at providing training and counselling to AATD (Alpha-1 Antitrypsin Deficiency) Augmentation Therapy Market patients diagnosed with AATD. Grifols stated that with AlfaCare, it aims to encourage new habits in patients and help them manage their disease properly. Research studies have proven that a huge percentage of people diagnosed with AATD were unaware about the symptoms, effects, and ways to treat the disorder. AlfaCare was launched to overcome all such shortcomings and improve the quality of patient care, thereby ascertaining reduced fatality rate of AATD. Thus, AlfaCare has transformed AATD augmentation therapies worldwide and is likely to boost the global AATD augmentation therapy market in the forecast period.

Request a Sample Copy of the Global Alpha-1 antitrypsin deficiency Augmentation Therapy Market Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/aatd-augmentation-therapy-market-100169

KEY PLAYERS COVERED

Some of the major companies that are present in the global alpha-1 antitrypsin deficiency Therapy market are Grifols, CSL, Baxter, Kamada, Takeda, Abeona Therapeutics.

Some of the major companies that are present in the Global Alpha-1 Antitrypsin Deficiency Therapy Market are;

  • Grifols S.A.
  • CSL Limited
  • Baxter
  • Kamada Ltd.
  • Takeda Pharmaceutical Company Limited
  • Abeona Therapeutics Inc., and other players.

Highlights of the Report

  • In-depth analysis of various insights, namely, Alpha-1 antitrypsin deficiency Augmentation Therapy Market trends, growth drivers, opportunities, and other related challenges.
  • Comprehensive details of key market players, their core competencies, and market shares.
  • The potency of suppliers and buyers to make better business decisions.
  • Lists out the market size in terms of volume. 

Segmentation:

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Stores

By Route of Administration

  • Oral
  • Injection
  • Inhalation

By Drug Class

  • Alpha-1 proteinase inhibitor
  • Bronchodilators
  • Steroids
  • Antibiotics

More Trending Topics From Fortune Business [email protected]

Global Lung Cancer Surgical Treatment Market Perspective with Study of Key Players & Revenue to Steady Growth Forecast To 2020

Drugs of Abuse Testing Market share research by applications and regions from 2020 to 2026 | Business | Fortune Business Insights

Global Neurovascular Catheters Market: Technological Advancements in Catheters to Boost Growth, says Fortune Business Insights

Dale Martinez

Dale possesses an engineering degree in Electronics from the Georgia Institute of Technology. She is the sole contributor at the Healthcare IT column. Before opting to write, Dale worked at major firms such as Microsoft, Amazon, GE, Raytheon, and so on. She possesses vast knowledge about a variety of fields like IT, IoT, Telecommunications, Health Dialysis, photovoltaic, and many others. Dale is also a ballet dancer.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Close